SMS Lifesciences India Past Earnings Performance
Past criteria checks 0/6
SMS Lifesciences India's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 0.6% per year. SMS Lifesciences India's return on equity is 1.1%, and it has net margins of 1.7%.
Key information
-5.3%
Earnings growth rate
-5.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -0.6% |
| Return on equity | 1.1% |
| Net Margin | 1.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SMS Lifesciences India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,797 | 49 | 486 | 0 |
| 30 Sep 23 | 3,121 | 46 | 475 | 0 |
| 30 Jun 23 | 3,079 | 67 | 448 | 0 |
| 31 Mar 23 | 3,156 | 115 | 440 | 0 |
| 31 Dec 22 | 3,475 | 189 | 427 | 0 |
| 30 Sep 22 | 3,505 | 172 | 421 | 0 |
| 30 Jun 22 | 3,558 | 247 | 414 | 0 |
| 31 Mar 22 | 3,501 | 253 | 401 | 0 |
| 31 Dec 21 | 3,366 | 213 | 381 | 0 |
| 30 Sep 21 | 3,118 | 216 | 351 | 0 |
| 30 Jun 21 | 2,871 | 147 | 334 | 0 |
| 31 Mar 21 | 2,656 | 136 | 308 | 0 |
| 31 Dec 20 | 2,291 | 106 | 290 | 0 |
| 30 Sep 20 | 2,091 | 76 | 271 | 0 |
| 30 Jun 20 | 2,237 | 79 | 265 | 0 |
| 31 Mar 20 | 2,608 | 102 | 267 | 0 |
| 31 Dec 19 | 3,220 | 127 | 264 | 0 |
| 30 Sep 19 | 3,970 | 188 | 272 | 0 |
| 30 Jun 19 | 4,098 | 195 | 241 | 0 |
| 31 Mar 19 | 3,779 | 178 | 236 | 0 |
| 31 Dec 18 | 2,997 | 146 | 204 | 0 |
| 30 Sep 18 | 2,697 | 119 | 194 | 0 |
| 30 Jun 18 | 2,315 | 85 | 186 | 0 |
| 31 Mar 18 | 2,130 | 65 | 179 | 0 |
| 31 Dec 17 | 2,148 | 72 | 179 | 0 |
| 30 Jun 17 | 2,034 | 90 | 180 | 0 |
| 31 Mar 17 | 2,159 | 129 | 171 | 0 |
Quality Earnings: 540679 has a large one-off gain of ₹23.5M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 540679's current net profit margins (1.7%) are lower than last year (5.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540679's earnings have declined by 5.3% per year over the past 5 years.
Accelerating Growth: 540679's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 540679 had negative earnings growth (-74.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.3%).
Return on Equity
High ROE: 540679's Return on Equity (1.1%) is considered low.